Drugs / RO4995819
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01901159 | Jun → Nov 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01409369 | Aug 2011 → Feb 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01457664 | Jul → Dec 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01367756 | May → Sep 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01457677 | Dec 2011 → Jun 2014 | major depressive disorder | Hoffmann-La Roche | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01733654 Comparator | Sep 2012 → Dec 2013 | major depressive disorder | Stanford University | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO4995819 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01457664 ↗ |
| Known as | Rg1578 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301593 ↗ |
| Action | Inhibit | “mGlu2/3 antagonism” NCT01733654 ↗ |
| Modality | Small molecule | — CHEMBL3301593 ↗ |
| Route | Oral | “multiple oral doses, Days 10-16” NCT01367756 ↗ |
| Target | GRM2 | “Metabotropic glutamate receptor 2 modulator” CHEMBL3301593 ↗ |
| Target | GRM3 | “Metabotropic glutamate receptor 3 modulator” CHEMBL3301593 ↗ |